Vaxcyte

VAXCYTE INC

Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.

chart investors ai

Broad U.S. Equity ETFs

Trading Ideas

ETFs

CRDO

FTAI

INSM

PCVX

RKLB

UFPI

Investors are questioning the value of small-cap stocks, as reflected by Russell 2000&#39;s 15% drop. Some top stocks saw even bigger declines.

Are Small-Cap Stocks A Buy After Russell 2000 Correction?

Xpeng g6 SUV

Large Cap

News

Movers

ABBV

CACI

LDOS

MNDY

MPWR

MRNA

NVDA

SMCI

XPEV

10 worst performing large-cap stocks last week: MPWR, SMCI, MRNA, LDOS, MNDY, PCVX, BAH, ABBV, CACI, XPEV. Check if they&#39;re in your portfolio.

Super Micro Computer, Moderna And XPeng Were Among Top 10 Large Cap Stocks Losing Big Last Week (November 11-15): Check Out Other Losers

movers image

Intraday Update

Markets

AAOI

AGMH

AIXI

AMAT

APDN

ASST

ATPC

AUUD

AVTX

BNRG

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CNFR

FEDU

GERN

INTC

IOBT

KROS

LITB

MNOV

MRVL

MSGM

NVAX

NVCR

NVMI

PSNY

QNTM

RXRX

SGRP

SHLS

SIFY

SLXN

STRL

TCBP

WINT

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Vaxcyte Inc

Earnings

Press Releases

Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update

Health Care

Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

General

Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

Legal

Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm

Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Guggenheim

Needham

Goldman Sachs

Mizuho

B of A Securities

Comments

Vaxcyte

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga